Recipharm AB publishes its interim report January - June 2018
April – June 2018 · Net sales amounted to SEK 1,701 million (1,401), an increase of 21% · EBITDA increased by 27% and amounted to SEK 307 million (242) corresponding to an EBITDA margin of 18.1% (17.3) · Operating profit (EBIT) amounted to SEK 262 million (123) · Profit after tax amounted to SEK 165 million (76) corresponding to a net margin of 9.7% (5.4) · Earnings per share amounted to SEK 2.59 (1.19) before dilution and SEK 2.59 (1.19) after dilution · Acquisition of the remaining 26% minority shares in Nitin Lifesciences Ltd · New share issue raising proceeds of